<html><head></head><body><h1>Potassium Supplements</h1><p class="drug-subtitle"><b>Class:</b> Replacement Preparations<br/>
<b>CAS Number:</b> 127-08-2<br/>
<b>Brands:</b> Effer-K, Kaon-Cl, Kay Ciel, K-Lor, Klor-Con, Klor-Con/EF, Klotrix, K-Tab, Micro-K</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>A source of potassium, an essential nutrient cation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Potassium Supplements</h2><h3>Hypokalemia</h3><p>Treatment or prevention of hypokalemia (potassium deficiency) in patients in whom dietary measures are inadequate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Conditions that may indicate or result in potassium deficiency include vomiting, diarrhea, drainage of GI fluids, hyperadrenalism, malnutrition, debilitation, prolonged negative nitrogen balance, prolonged parenteral alimentation without addition of potassium, dialysis, metabolic alkalosis, metabolic or diabetic acidosis, GI tract abnormalities that result in poor absorption, certain renal diseases, and familial periodic paralysis characterized by hypokalemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium should be included in long-term electrolyte replacement regimens and has been recommended for routine prophylactic administration following surgery after adequate urine flow has been established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium replacement may be indicated in patients receiving certain drugs that may sometimes cause potassium depletion (e.g., thiazide diuretics, carbonic anhydrase inhibitors, loop diuretics, some corticosteroids, corticotropin, aminosalicylic acid, amphotericin B).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although ingestion of potassium-rich foods and/or use of potassium-containing salt substitutes may prevent potassium depletion in patients receiving potassium-depleting drugs, judicious prophylactic administration of potassium may be advisable in selected patients during prolonged diuretic or corticosteroid therapy, especially if they are digitalized.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium chloride usually is the salt of choice in the treatment of potassium depletion, since the chloride ion is required to correct hypochloremia which frequently accompanies potassium deficiency and since the citrate, bicarbonate, gluconate, or another alkalinizing salt of potassium may cause hypochloremia, particularly when used in conjunction with chloride-restricted diets.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alkalinizing potassium salts (acetate, bicarbonate, citrate, gluconate) should be used for treatment of hypokalemia in patients with metabolic acidosis (e.g., renal tubular acidosis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;g&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><b>Potassium also is available as the potassium phosphate salt; however, potassium phosphate usually is used to replace phosphate losses or to correct coexisting hypokalemia and hypophosphatemia.</b>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;q&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;r&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;s&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;t&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Hypertension</h3><p>Inadequate dietary intake of potassium plays an important role in the development of hypertension,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and high dietary intake of potassium (including use of potassium supplements) may protect against the development of high blood pressure and improve blood pressure control in patients with hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Most experts recommend enhanced intake of potassium&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (3.5–5 g daily)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; in hypertensive patients as part of lifestyle modifications unless contraindicated by chronic kidney disease (CKD) or use of drugs that reduce potassium excretion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions: Precautions and Contraindications.) Increased potassium intake is recommended particularly in those unable to adequately reduce their sodium intake.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adequate intake of potassium should be considered as a means of preventing the development of hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Food sources high in potassium such as fruits and vegetables&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;104&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; are preferred over potassium supplements.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Arrhythmias</h3><p>Potassium salts may be used cautiously to abolish arrhythmias of cardiac glycoside toxicity precipitated by a loss of potassium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Elevation of plasma potassium concentrations by 0.5–1.5 mEq/L or to the ULN may be useful in the management of tachyarrhythmias following cardiac surgery,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but this strategy should <i>not</i> be used in patients with atrioventricular block since potassium may further impair nodal conduction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Thallium Toxicity</h3><p>IV potassium supplements, usually potassium chloride,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;35&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;h&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;i&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;j&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; have been used in the management of thallium poisoning† to enhance diuresis and mobilize thallium from tissues;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;h&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; such treatment is limited by the amount of thallium that can be released into the blood without worsening cerebral symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Potassium Supplements Dosage and Administration</h2><h3>Administration</h3><p>Administer orally or by slow IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Potassium-containing injections (usually potassium chloride),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;k&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;m&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;n&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; have been administered by hypodermoclysis† (into subcutaneous tissues).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;k&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;l&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;m&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;n&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;o&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium acetate, bicarbonate, chloride, citrate, and gluconate can be administered orally.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Potassium acetate and chloride can be administered IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Whenever possible, potassium supplements should be given orally since the relatively slow absorption from the GI tract prevents sudden, large increases in plasma potassium concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Replace IV potassium therapy with oral supplements and/or ingestion of potassium-rich foods as soon as possible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Oral potassium supplements should preferably be administered with or after meals with a full glass of water or fruit juice to minimize the possibility of GI irritation and a saline cathartic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usually administered orally in 1–4 doses daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Daily dosage &gt;20 mEq should be divided into several doses and should not be given as a single dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;g&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Powders or tablets for oral solution should be dissolved and/or diluted and administered according to the manufacturers’ directions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;g&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Extended-release potassium chloride preparations should be reserved for use in patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for those in whom there is a problem of compliance with these latter dosage forms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Close monitoring of ECG and plasma potassium concentrations is <i>essential</i> during IV administration of potassium, especially when the rate of administration is &gt;20 mEq/hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hyperkalemia under Cautions.)</p><p>Potassium IV solutions should generally be administered only in patients with adequate urine flow (e.g., administer to postoperative patients only after adequate urine flow established).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In dehydrated patients, 1 liter of potassium-free fluid should be administered prior to initiating potassium therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Local vascular intolerance may limit the ability to administer concentrated solutions; administer via large, high-flow vein (e.g., femoral vein) or administer less concentrated solutions in divided doses via 2 veins simultaneously.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Avoid</i> administration of concentrated potassium solutions via subclavian, jugular, or right atrial catheter; local potassium concentrations achieved in the heart may be high and potentially cardiotoxic.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium chloride injection in plastic containers should <i>not</i> be used in series connections with other plastic containers, since such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from the secondary container is complete.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hyperkalemia has been reported when concentrated potassium chloride solutions were added to IV infusions from a hanging flexible plastic container, apparently as a result of pooling of the concentrated potassium solution at the base of the container and infusion of undiluted solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Squeezing the container does not facilitate mixing but tends to pump the concentrated solution into the infusion chamber.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Such solutions must be carefully mixed by inverting the plastic container during the addition of potassium solutions with subsequent agitation and/or kneading to prevent pooling.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Potassium acetate and potassium chloride are available as concentrates that <i>must</i> be diluted prior to IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Generally, potassium concentrations in IV fluids should not exceed 40 mEq/L.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, higher potassium concentrations (e.g., 60–80 mEq/L) occasionally may be needed initially for management of severe hypokalemia and associated cardiac arrhythmias, diabetic ketoacidosis or diuretic phase of acute renal failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Must be administered by slow IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Generally, rate of administration should not exceed 20 mEq/hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>More rapid administration occasionally may be necessary for management of severe hypokalemia and associated cardiac arrhythmias or diabetic ketoacidosis or diuretic phase of acute renal failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If administered by hypodermoclysis†, potassium concentrations should not exceed 10 mEq/L to avoid local pain.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Dosage of potassium supplements usually expressed as mEq of potassium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Normal adult daily potassium requirement and usual dietary intake of potassium is 40–80 mEq; infants may require 2–3 mEq/kg or 40 mEq/m<sup>2</sup> daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage must be carefully individualized according to the patient’s requirements and response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To avoid serious hyperkalemia, replacement of potassium deficits must be undertaken gradually, usually over a 3- to 7-day period depending on the severity of the deficit.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium replacement requirements can be estimated only by clinical condition and response, ECG monitoring, and/or plasma potassium determinations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>40 mEq of potassium is provided by approximately:</p><p>3.9 g of potassium acetate</p><p>4.0 g of potassium bicarbonate</p><p>3.0 g of potassium chloride</p><p>4.3 g of potassium citrate</p><p>9.4 g of potassium gluconate</p><p>If used in pediatric patients†, do not exceed 3 mEq/kg daily in young children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Average dosage approximately 20 mEq daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usually should not exceed 200 mEq daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;p&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual dosage is 40–100 mEq or more daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usually should not exceed 200 mEq daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;p&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>3 mEq/kg daily for young children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usually should not exceed 200 mEq daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;p&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Cautious dosage selection and careful monitoring recommended in patients with renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Select dosage with caution, starting at low end of dosage range, because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Potassium Supplements</h2><h3>Contraindications</h3><ul>
<li>
<p>Hyperkalemia, including that complicating chronic renal failure, systemic acidosis (e.g., diabetic acidosis), acute dehydration, extensive tissue breakdown (e.g., in severe burns), adrenal insufficiency, or concomitant use of potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;g&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Severe renal impairment with oliguria, anuria, or azotemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Use of solid oral dosage preparations in patients with structural, pathologic (e.g., diabetic gastroparesis), and/or pharmacologic (e.g., induced by anticholinergic agents) causes for arrest or delay in GI transit.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Use of extended-release preparations in patients with esophageal compression caused by an enlarged left atrium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Hyperkalemia, including that complicating chronic renal failure, systemic acidosis (e.g., diabetic acidosis), acute dehydration, extensive tissue breakdown (e.g., in severe burns), adrenal insufficiency, or concomitant use of potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;g&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe renal impairment with oliguria, anuria, or azotemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use of solid oral dosage preparations in patients with structural, pathologic (e.g., diabetic gastroparesis), and/or pharmacologic (e.g., induced by anticholinergic agents) causes for arrest or delay in GI transit.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use of extended-release preparations in patients with esophageal compression caused by an enlarged left atrium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Hyperkalemia and cardiac arrest can occur following use of potassium supplements in patients with impaired mechanisms for excreting potassium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Most common and serious adverse effect of potassium therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potentially fatal; can develop rapidly and patients may be asymptomatic.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Occurs most frequently with IV potassium (especially if administered too rapidly),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but may occur with oral potassium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use IV solutions containing potassium with extreme caution, if at all, in patients with hyperkalemia, severe renal failure, or other conditions with potassium retention.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Evaluate renal function before therapy; monitor clinical status with periodic ECGs and/or determinations of plasma potassium concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Clinical signs and symptoms of hyperkalemia include paresthesia of the extremities, listlessness, mental confusion, weakness or heaviness of the legs, flaccid paralysis, cold skin, gray pallor, peripheral vascular collapse with fall in blood pressure, cardiac arrhythmias, and heart block.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients who have both hypokalemia and metabolic acidosis, an alkalinizing potassium salt (acetate, bicarbonate, citrate, gluconate) should be used for treatment of hypokalemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;g&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use of IV solutions containing potassium may cause fluid and/or solute overload, leading to decreased electrolyte concentrations, overhydration, congestion, and pulmonary edema.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use IV solutions containing potassium with extreme caution, if at all, in patients with CHF, severe renal insufficiency, or other conditions with sodium retention and edema.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Solid oral dosage forms of potassium have resulted in ulcerative and/or stenotic GI lesion; perforation has occurred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Possibly more frequent with enteric-coated tablets (no longer commercially available in the US).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer wax matrix and extended-release preparations with caution; discontinue immediately if abdominal pain, distention, severe vomiting, or GI bleeding occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reserve use of extended-release potassium chloride preparations for patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for those in whom there is a problem of compliance with these latter dosage forms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some experts question the use of any solid potassium preparation, since use of dilute liquid preparations minimizes the risk of GI complications.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pain and phlebitis may occur at IV administration site, especially with potassium solutions containing ≥30 mEq/L.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor fluid balance, electrolyte concentrations, and acid-base balance periodically during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Regular serum potassium determinations are recommended, especially in patients with renal impairment or diabetic nephropathy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When potassium is administered IV in parenteral solutions, consider the cautions, precautions, and contraindications associated with fluid volume and electrolytes contained in the IV infusion fluid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether potassium is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Response in patients ≥65 years of age does not appear to differ from that in younger adults; however, use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Parenteral solutions containing potassium may cause sodium and/or potassium retention.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use cautiously; monitor plasma potassium concentrations frequently.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Hyperkalemia; GI effects (nausea, vomiting, diarrhea, flatulence, abdominal pain or discomfort); infusion site reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Potassium Supplements</h2><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>ACE inhibitors (e.g., captopril, enalapril)</p><p>Increased risk of hyperkalemia&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use concomitantly only if monitored closely; monitor serum potassium frequently &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Corticosteroids</p><p>Use caution when used concomitantly with parenteral solutions containing potassium &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Corticotropin (ACTH)</p><p>Use caution when used concomitantly with parenteral solutions containing potassium &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diuretics, potassium-sparing (e.g. amiloride, spironolactone, triamterene)</p><p>Increased risk of severe hyperkalemia&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant use contraindicated&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Potassium Supplements Pharmacokinetics</h2><h3>Absorption</h3><p>Well absorbed following oral administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following oral administration of extended-release formulations, potassium is released slowly; risk of high, localized concentrations is minimized.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Normal plasma potassium concentrations generally range from 3.5–5 mEq/L in healthy adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Plasma concentrations up to 7.7 mEq/L may be normal in neonates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Plasma potassium concentrations are not necessarily indicative of cellular potassium concentrations; cellular deficits may occur without concomitant decreases in plasma potassium concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hypokalemia may occur without substantial depletion of cellular potassium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Extracellular fluid pH changes produce reciprocal effects on plasma potassium concentrations; 0.1 unit increase in plasma pH produces a decrease of 0.6 mEq/L in plasma potassium concentration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Enters extracellular fluid and actively transported into cells; intracellular concentration is up to 40 times extracellular concentration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Intracellular movement augmented by dextrose, insulin, and oxygen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium concentrations in gastric and intestinal secretions are higher than plasma concentrations; diarrheal fluid may contain up to 60 mEq/L.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Excreted principally in urine; small amounts may be excreted via the skin and intestinal tract.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Filtered by the glomeruli, reabsorbed in the proximal tubule, and secreted in the distal tubule, the site of sodium-potassium exchange.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tubular secretion influenced by chloride ion concentration, hydrogen ion exchange, acid-base equilibrium, and adrenal hormones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Healthy adults on potassium-free diets usually excrete 40–50 mEq of potassium daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potassium excretion decreased in patients with renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Surgery and/or tissue injury result in increased urinary excretion of potassium which may continue for several days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Postoperative patients or patients under stress of disease with normal kidneys may excrete up to 80–90 mEq of potassium daily, even though they are not receiving any potassium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Tight, light resistant containers at 15–30°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–30°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–30°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>25°C (may be exposed to 15–30°C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>25°C (may be exposed to up to 40°C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Metoclopramide HCl</p><p>Compatible</p><p>Ciprofloxacin</p><p>Compatible</p><p>Dextrose–Ringer’s injection combinations</p><p>Dextrose–Ringer’s injection, lactated, combinations</p><p>Dextrose 5% in Ringer’s injection, lactated</p><p>Dextrose–saline combinations</p><p>Dextrose 5% in sodium chloride 0.9%</p><p>Dextrose 2.5, 5, 10, or 20% in water</p><p>Ionosol products</p><p>Ringer’s injection</p><p>Ringer’s injection, lactated</p><p>Sodium chloride 0.45 or 0.9%</p><p>Sodium lactate 1/6 M</p><p>Variable</p><p>Fat emulsion 10%, IV</p><p>Compatible</p><p>Amikacin sulfate</p><p>Aminophylline</p><p>Amiodarone HCl</p><p>Atracurium besylate</p><p>Calcium gluconate</p><p>Cefepime HCl</p><p>Ceftazidime</p><p>Chloramphenicol sodium succinate</p><p>Ciprofloxacin</p><p>Clindamycin phosphate</p><p>Cytarabine</p><p>Dimenhydrinate</p><p>Dopamine HCl</p><p>Enalaprilat</p><p>Erythromycin lactobionate</p><p>Fluconazole</p><p>Foscarnet sodium</p><p>Fosphenytoin sodium</p><p>Furosemide</p><p>Heparin sodium</p><p>Hydrocortisone sodium succinate</p><p>Hydromorphone HCl</p><p>Isoproterenol HCl</p><p>Lidocaine HCl</p><p>Magnesium sulfate</p><p>Methyldopate HCl</p><p>Metoclopramide HCl</p><p>Mitoxantrone HCl</p><p>Nafcillin sodium</p><p>Nicardipine HCl</p><p>Norepinephrine bitartrate</p><p>Oxacillin sodium</p><p>Penicillin G potassium</p><p>Phenylephrine HCl</p><p>Ranitidine HCl</p><p>Sodium bicarbonate</p><p>Vancomycin HCl</p><p>Verapamil HCl</p><p>Incompatible</p><p>Amphotericin B</p><p>Variable</p><p>Dobutamine HCl</p><p>Penicillin G sodium</p><p>Compatible</p><p>Acyclovir sodium</p><p>Allopurinol sodium</p><p>Amifostine</p><p>Aminophylline</p><p>Amiodarone HCl</p><p>Ampicillin sodium</p><p>Anidulafungin</p><p>Atropine sulfate</p><p>Aztreonam</p><p>Bivalirudin</p><p>Calcium gluconate</p><p>Caspofungin acetate</p><p>Ceftaroline fosamil</p><p>Chlorpromazine HCl</p><p>Ciprofloxacin</p><p>Cisatracurium besylate</p><p>Cladribine</p><p>Clonidine HCl</p><p>Cyanocobalamin</p><p>Dexamethasone sodium phosphate</p><p>Dexmedetomidine HCl</p><p>Digoxin</p><p>Diltiazem HCl</p><p>Diphenhydramine HCl</p><p>Dobutamine HCl</p><p>Docetaxel</p><p>Dopamine HCl</p><p>Doripenem</p><p>Doxorubicin HCl liposome injection</p><p>Droperidol</p><p>Edrophonium chloride</p><p>Enalaprilat</p><p>Epinephrine HCl</p><p>Ertapenem sodium</p><p>Esmolol HCl</p><p>Estrogens, conjugated</p><p>Ethacrynate sodium</p><p>Etoposide phosphate</p><p>Famotidine</p><p>Fenoldopam mesylate</p><p>Fentanyl citrate</p><p>Filgrastim</p><p>Fludarabine phosphate</p><p>Fluorouracil</p><p>Furosemide</p><p>Gallium nitrate</p><p>Gemcitabine HCl</p><p>Gentamicin sulfate</p><p>Granisetron HCl</p><p>Heparin sodium</p><p>Hetastarch in lactated electrolyte injection (Hextend)</p><p>Hydralazine HCl</p><p>Hydroxyethyl starch 130/0.4 in sodium chloride 0.9%</p><p>Idarubicin HCl</p><p>Indomethacin sodium trihydrate</p><p>Isoproterenol HCl</p><p>Labetalol HCl</p><p>Levofloxacin</p><p>Lidocaine HCl</p><p>Linezolid</p><p>Lorazepam</p><p>Magnesium sulfate</p><p>Melphalan HCl</p><p>Meperidine HCl</p><p>Meropenem</p><p>Micafungin sodium</p><p>Midazolam HCl</p><p>Milrinone lactate</p><p>Morphine sulfate</p><p>Neostigmine methylsulfate</p><p>Nicardipine HCl</p><p>Norepinephrine bitartrate</p><p>Ondansetron HCl</p><p>Oxacillin sodium</p><p>Oxaliplatin</p><p>Oxytocin</p><p>Paclitaxel</p><p>Palonosetron HCl</p><p>Pantoprazole sodium</p><p>Pemetrexed disodium</p><p>Penicillin G potassium</p><p>Pentazocine lactate</p><p>Phytonadione</p><p>Piperacillin sodium–tazobactam sodium</p><p>Procainamide HCl</p><p>Prochlorperazine edisylate</p><p>Propofol</p><p>Propranolol HCl</p><p>Quinupristin-dalfopristin</p><p>Remifentanil HCl</p><p>Sargramostim</p><p>Scopolamine HBr</p><p>Sodium bicarbonate</p><p>Sodium nitroprusside</p><p>Succinylcholine chloride</p><p>Tacrolimus</p><p>Telavancin HCl</p><p>Teniposide</p><p>Theophylline</p><p>Thiotepa</p><p>Tigecycline</p><p>Tirofiban HCl</p><p>Trimethobenzamide HCl</p><p>Vinorelbine tartrate</p><p>Warfarin sodium</p><p>Zidovudine</p><p>Incompatible</p><p>Amphotericin B cholesteryl sulfate complex</p><p>Azithromycin</p><p>Diazepam</p><p>Ergotamine tartrate</p><p>Phenytoin sodium</p><p>Variable</p><p>Aldesleukin</p><p>Methylprednisolone sodium succinate</p><p>Promethazine HCl</p><h2>Actions</h2><ul>
<li>
<p>The major cation of intracellular fluid; essential for maintenance of acid-base balance, isotonicity, and electrodynamic cellular function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Important activator in many enzymatic reactions; essential for transmission of nerve impulses; contraction of cardiac, smooth, and skeletal muscles; gastric secretion; renal function; tissue synthesis; and carbohydrate metabolism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Reduces mean SBP and DBP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>The major cation of intracellular fluid; essential for maintenance of acid-base balance, isotonicity, and electrodynamic cellular function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Important activator in many enzymatic reactions; essential for transmission of nerve impulses; contraction of cardiac, smooth, and skeletal muscles; gastric secretion; renal function; tissue synthesis; and carbohydrate metabolism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reduces mean SBP and DBP.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of advising patient to take oral supplement with meal and full glass of water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of taking only as prescribed; do not increase dosage or duration of therapy unless otherwise instructed by a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinician of tarry stools or other GI symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinician of difficulty swallowing capsules or if capsules seem to become stuck in throat.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patient to swallow capsules and not crush, chew, or suck capsules.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of advising patient to take oral supplement with meal and full glass of water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of taking only as prescribed; do not increase dosage or duration of therapy unless otherwise instructed by a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinician of tarry stools or other GI symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinician of difficulty swallowing capsules or if capsules seem to become stuck in throat.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patient to swallow capsules and not crush, chew, or suck capsules.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>For injection concentrate</p><p>2 mEq of K<sup>+</sup>/mL and CH<sub>3</sub>COO<sup>-</sup>/mL*</p><p>Potassium Acetate Injection</p><p>2 mEq of K<sup>+</sup>/mL and CH<sub>3</sub>COO<sup>-</sup>/mL pharmacy bulk package*</p><p>Potassium Acetate Injection</p><p>Potassium Acetate Injection MaxiVial<sup></sup></p><p>Abraxis</p><p>4 mEq of K<sup>+</sup>/mL and CH<sub>3</sub>COO<sup>-</sup>/mL*</p><p>Potassium Acetate Injection</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets, for solution</p><p>10 mEq of K<sup>+</sup></p><p>Effer-K<sup></sup></p><p>Nomax</p><p>20 mEq of K<sup>+</sup></p><p>Effer-K<sup></sup></p><p>Nomax</p><p>25 mEq of K<sup>+</sup>*</p><p>Klor-Con<sup></sup>/EF</p><p>Upsher-Smith</p><p>Potassium Bicarbonate Effervescent Tablets</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Capsules, extended-release</p><p>8 mEq of K<sup>+</sup> and Cl<sup>−</sup></p><p>Micro-K<sup></sup></p><p>Ther-Rx</p><p>10 mEq of K<sup>+</sup> and Cl<sup>−</sup>*</p><p>Micro-K<sup></sup></p><p>Ther-Rx</p><p>Potassium Chloride Extended-Release Capsules</p><p>For solution</p><p>20 mEq of K<sup>+</sup> and Cl<sup>−</sup> per packet*</p><p>K-Lor<sup></sup></p><p>Abbott</p><p>Kay Ciel<sup></sup></p><p>Forest</p><p>Klor-Con<sup></sup> Powder</p><p>Upsher-Smith</p><p>25 mEq of K<sup>+</sup> and Cl<sup>−</sup> per packet</p><p>Klor-Con<sup></sup>/25 Powder</p><p>Upsher-Smith</p><p>Solution</p><p>6.7 mEq of K<sup>+</sup>/5 mL and Cl<sup>-</sup>/5 mL*</p><p>Kay Ciel<sup></sup></p><p>Forest</p><p>Potassium Chloride Oral Solution</p><p>Potassium Chloride Oral Solution</p><p>Potassium Chloride Oral Solution ()</p><p>Potassium Chloride Oral Solution ()</p><p>13.3 mEq of K<sup>+</sup>/5 mL and Cl<sup>-</sup>/5 mL*</p><p>Potassium Chloride Oral Solution ()</p><p>Tablets, extended-release</p><p>10 mEq of K<sup>+</sup> and Cl<sup>−</sup></p><p>Kaon-Cl-10<sup></sup></p><p>Savage</p><p>Tablets, extended-release (containing coated potassium chloride crystals)</p><p>10 mEq of K<sup>+</sup> and Cl<sup>−</sup>*</p><p>Klor-Con<sup></sup> M10</p><p>Upsher-Smith</p><p>Potassium Chloride Extended-Release Tablets</p><p>15 mEq of K<sup>+</sup> and Cl<sup>−</sup></p><p>Klor-Con<sup></sup> M15 (scored)</p><p>Upsher-Smith</p><p>20 mEq of K<sup>+</sup> and Cl<sup>−</sup>*</p><p>Klor-Con<sup></sup> M20 (scored)</p><p>Upsher-Smith</p><p>Potassium Chloride Extended-Release Tablets (scored)</p><p>Potassium Chloride Extended-Release Tablets (scored)</p><p>Tablets, extended-release, film-coated</p><p>8 mEq of K<sup>+</sup> and Cl<sup>−</sup>*</p><p>Klor-Con<sup></sup> 8</p><p>Upsher-Smith</p><p>Potassium Chloride Extended-Release Tablets</p><p>10 mEq of K<sup>+</sup> and Cl<sup>−</sup>*</p><p>Klor-Con<sup></sup> 10</p><p>Upsher-Smith</p><p>Klotrix<sup></sup></p><p>Bristol-Myers Squibb</p><p>K-Tab<sup></sup> Filmtab<sup></sup></p><p>Abbott</p><p>Potassium Chloride Extended-Release Tablets</p><p>Parenteral</p><p>For injection concentrate</p><p>1.5 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL*</p><p>Potassium Chloride for Injection Concentrate</p><p>2 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL*</p><p>2 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL pharmacy bulk package*</p><p>Potassium Chloride for Injection Concentrate</p><p>Hospira</p><p>For injection concentrate, for IV infusion</p><p>0.1 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL (10 mEq)*</p><p>Potassium Chloride for Injection Concentrate</p><p>Potassium Chloride Injection Highly Concentrated (Viaflex<sup></sup>)</p><p>Baxter</p><p>0.2 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL (10 and 20 mEq)*</p><p>Potassium Chloride Injection Highly Concentrated (Viaflex<sup></sup>)</p><p>Baxter</p><p>0.3 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL (30 mEq)*</p><p>Potassium Chloride Injection Highly Concentrated (Viaflex<sup></sup>)</p><p>Baxter</p><p>0.4 mEq of K<sup>+</sup> and Cl<sup>−</sup> per mL (20 and 40 mEq)*</p><p>Potassium Chloride Injection Highly Concentrated (Viaflex<sup></sup>)</p><p>Baxter</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV infusion only</p><p>10 mEq of K<sup>+</sup> per L in 5% Dextrose*</p><p>10 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq of K<sup>+</sup> per L in 5% Dextrose*</p><p>20 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose Injection</p><p>Braun, Hospira</p><p>30 mEq of K<sup>+</sup> per L in 5% Dextrose*</p><p>30 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose Injection</p><p>Hospira</p><p>40 mEq of K<sup>+</sup> per L in 5% Dextrose*</p><p>40 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>40 mEq (0.3%) Potassium Chloride in 5% Dextrose Injection</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV infusion only</p><p>20 mEq of K<sup>+</sup> per L in 0.9% Sodium Chloride*</p><p>20 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq/L (0.15%) Potassium Chloride in 0.9% Sodium Chloride Injection</p><p>40 mEq of K<sup>+</sup> per L in 0.9% Sodium Chloride*</p><p>40 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>40 mEq/L (0.3%) Potassium Chloride in 0.9% Sodium Chloride Injection</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV infusion only</p><p>20 mEq of K<sup>+</sup> per L in 5% Dextrose and Lactated Ringer’s*</p><p>20 mEq/L Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection</p><p>40 mEq of K<sup>+</sup> per L in 5% Dextrose and Lactated Ringer’s*</p><p>40 mEq/L Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV infusion only</p><p>10 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.2–0.225% Sodium Chloride*</p><p>10 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>(0.075%) 10 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection</p><p>10 mEq/L (0.075%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection</p><p>10 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.3–0.33% Sodium Chloride*</p><p>10 mEq/L (0.075%) Potassium Chloride in 5% Dextrose and 3% Sodium Chloride Injection</p><p>10 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>10 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.45% Sodium Chloride*</p><p>10 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>10 mEq/L (0.075%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection</p><p>20 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.2–0.225% Sodium Chloride*</p><p>20 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection</p><p>(0.15%) 20 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection</p><p>20 mEq K<sup>+</sup> per L in 5% Dextrose and 0.3–0.33% Sodium Chloride*</p><p>20 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and 0.3% Sodium Chloride Injection</p><p>20 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.45% Sodium Chloride*</p><p>20 mEq Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection</p><p>20 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.9% Sodium Chloride*</p><p>20 mEq/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>20 mEq (0.15%) Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection</p><p>20 mEq of K<sup>+</sup> per L in 10% Dextrose and 0.2% Sodium Chloride*</p><p>(0.15%) 20 mEq/L Potassium Chloride in 10% Dextrose and 0.2% Sodium Chloride Injection</p><p>30 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.2–0.225% Sodium Chloride*</p><p>30 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection</p><p>(0.22%) 30 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection</p><p>30 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.3–0.33% Sodium Chloride*</p><p>30 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose and 0.3% Sodium Chloride Injection</p><p>30 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.45% Sodium Chloride*</p><p>30 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection</p><p>(0.22%) 30 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection</p><p>40 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.2–0.225% Sodium Chloride*</p><p>40 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection</p><p>(0.3%) 40 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection</p><p>40 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.3–0.33% Sodium Chloride*</p><p>40 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection</p><p>40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and 0.3% Sodium Chloride Injection</p><p>40 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.45% Sodium Chloride*</p><p>40 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection</p><p>40 mEq of K<sup>+</sup> per L in 5% Dextrose and 0.9% Sodium Chloride*</p><p>40 mEq/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection (Viaflex<sup></sup>)</p><p>Baxter</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV infusion only</p><p>0.1 mEq per mL (10 mEq)*</p><p>Potassium Chloride in Water for Injection (Premixed) (LifeCare<sup></sup>)</p><p>Hospira</p><p>0.2 mEq per mL (10 and 20 mEq)*</p><p>Potassium Chloride in Water for Injection (Premixed) (LifeCare<sup></sup>)</p><p>Hospira</p><p>0.3 mEq per mL (30 mEq)*</p><p>Potassium Chloride in Water for Injection (Premixed) (LifeCare<sup></sup>)</p><p>Hospira</p><p>0.4 mEq per mL (20 and 40 mEq)*</p><p>Potassium Chloride in Water for Injection (Premixed) (LifeCare<sup></sup>)</p><p>Hospira</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets, for solution</p><p>25 mEq of K<sup>+</sup> and Cl<sup>−</sup> (provided by potassium bicarbonate 0.5 g and potassium chloride 1.5 g)*</p><p>Potassium Effervescent Tablets</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions March 25, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>25. Travenol Laboratories, Inc. Travenol Guide to Fluid Therapy. 1973 May.</p><p>34. Bank WJ, Pleasure DE, Suzuki K et al. Thallium poisoning. <i>Arch Neurol</i>. 1972; 26:456-64. http://www.ncbi.nlm.nih.gov/pubmed/4337304?dopt=AbstractPlus</p><p>35. Cavanagh JB, Fuller NH, Johnson HRM et al. The effects of thallium salts, with particular reference to the nervous system changes: a report of three cases. <i>Q J Med</i>. 1974; 43:293-319. http://www.ncbi.nlm.nih.gov/pubmed/4369306?dopt=AbstractPlus</p><p>102. Stamler R, Stamler J, Grandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. <i>Am J Clin Nutr</i>. 1997; 65(Suppl):338-65S.</p><p>103. Whelton PK, He J, Cutler JA et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. <i>JAMA</i>. 1997; 277:1624-32. http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=AbstractPlus</p><p>104. Appel LJ, Moore TJ, Obarzanek E et al for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. <i>N Engl J Med</i>. 1997; 336:1117-24. http://www.ncbi.nlm.nih.gov/pubmed/9099655?dopt=AbstractPlus</p><p>1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus</p><p>a. AHFS Drug Information 2004. McEvoy, GK, ed. Potassium Supplements. Bethesda, MD: American Society of Health-System Pharmacists; 2004:2517-23.</p><p>HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:956-67.</p><p>c. Ethex. Potassium chloride extended-release capsules, USP 10 mEq (750 mg) prescribing information. St Louis, MO; 2003 Sept.</p><p>d. Baxter. Potassium chloride in sodium chloride injection, USP prescribing information. Deerfield, IL; 2003 May.</p><p>e. Baxter. Highly concentrated potassium chloride injection prescribing information. Deerfield, IL; 2003 Feb.</p><p>f. Forest. Kay Ciel<sup></sup> (potassium chloride) oral solution 10% and powder prescribing information. St Louis, MO; 1999 April.</p><p>g. Abbott. L-Lor<sup></sup> (potassium chloride) powder packets prescribing information. St Louis, MO; 1994 Jun.</p><p>h. Malbrain ML, Lambrecht GL, Zandijk E et al. Treatment of severe thallium intoxication. <i>J Toxicol Clin Toxicol</i>. 1997; 35:97-100. http://www.ncbi.nlm.nih.gov/pubmed/9022660?dopt=AbstractPlus</p><p>i. Moore D, House I, Dixon A. Thallium poisoning: diagnosis may be elusive but alopecia is the clue. <i>BMJ</i>. 1993; 306:1527-9. http://www.ncbi.nlm.nih.gov/pubmed/8518684?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1677968&amp;blobtype=pdf</p><p>j. Galván-Arzate S, Santamaría A. Thallium toxicity. <i>Toxicol Lett</i>. 1998; 99:1-13. http://www.ncbi.nlm.nih.gov/pubmed/9801025?dopt=AbstractPlus</p><p>k. Sasson M, Shvartzman P. Hypodermoclysis: an alternative infusion technique. <i>Am Fam Physician</i>. 2001; 64:1575-8. http://www.ncbi.nlm.nih.gov/pubmed/11730312?dopt=AbstractPlus</p><p>l. Pirrello RD, Ting Chen C, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase. <i>J Palliat Med</i>. 2007; 10:861-4. http://www.ncbi.nlm.nih.gov/pubmed/17803404?dopt=AbstractPlus</p><p>m. Rochon PA, Gill SS, Litner J et al. A systematic review of the evidence for hypodermoclysis to treat dehydration in older people. <i>J Gerontol A Biol Sci Med Sci</i>. 1997; 52:M169-76. http://www.ncbi.nlm.nih.gov/pubmed/9158559?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1965283&amp;blobtype=pdf</p><p>n. Ferry M, Dardaine V, Constans T. Subcutaneous infusion or hypodermoclysis: a practical approach. <i>J Am Geriatr Soc</i>. 1999; 47:93-5. http://www.ncbi.nlm.nih.gov/pubmed/9920236?dopt=AbstractPlus</p><p>o. Berger EY. Nutrition by hypodermoclysis. <i>J Am Geriatr Soc</i>. 1984; 32:199-203. http://www.ncbi.nlm.nih.gov/pubmed/6421919?dopt=AbstractPlus</p><p>p. Kokko JP. Fluids and Electrolytes. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine. 22nd ed. Philadelphia: Saunders; 2004:669-87.</p><p>q. Sedlacek M, Schoolwerth AC, Remillard BD. Electrolyte disturbances in the intensive care unit. <i>Semin Dial</i>. 2006; 19:496-501. http://www.ncbi.nlm.nih.gov/pubmed/17150050?dopt=AbstractPlus</p><p>r. Gennari FJ. Hypokalemia. <i>N Engl J Med</i>. 1998; 339:451-8. http://www.ncbi.nlm.nih.gov/pubmed/9700180?dopt=AbstractPlus</p><p>s. Kraft MD, Btaiche IF, Sacks GS et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005; 62:1663-82. http://www.ncbi.nlm.nih.gov/pubmed/16085929?dopt=AbstractPlus</p><p>t. Rastegar A, Soleimani M, Rastergar A. Hypokalaemia and hyperkalaemia. <i>Postgrad Med J</i>. 2001; 77:759-64. http://www.ncbi.nlm.nih.gov/pubmed/11723313?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1742191&amp;blobtype=pdf</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>